Healthcare (HC)

BOSTON, and SAN FRANCISCO, January 2, 2018– PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that it has successfully closed a $50 million Series B financing led by Temasek. With this financing, Temasek joins new and existing investors including 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, Singapore-based EDBI, and the Bridge Builder’s Collaborative.

SINGAPORE – 20 December 2017 – Tessa Therapeutics, an international clinical stage biopharmaceutical company focusing on T cell therapy for solid tumors, today announced the completion of a USD 80 million financing round led by Temasek, an investment company headquartered in Singapore, and joined by EDBI, Karst Peak Capital, Heliconia, Heritas and other investors.

IRVINE, CA–(Marketwired – Oct 31, 2017) – Ivantis Inc., developer of the novel Hydrus™ Microstent, a device designed to lower eye pressure for open-angle glaucoma patients, announced today that it has submitted its final Pre-Market-Approval (PMA) module to the U.S. Food and Drug Administration (FDA) for market approval.

DENVER, Aug. 16, 2017 /PRNewswire/ — Welltok, the leading consumer health enterprise Software as a Service company, is among the top 5 percent of the nation’s fastest growing private companies on Inc. magazine’s 36th annual list.

SINGAPORE, 8 August 2017 – QT Vascular Ltd. (the “Company” or “QT Vascular”, and together with its subsidiaries, the “Group”), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today that it achieved revenue growth of 47.8% to US$3.5 million for the three months ended 30 June 2017 (“2Q2017”).

Singapore, 28 June 2017 – MerLion Pharmaceuticals (“MerLion”) today announced that a joint project with the Defence Science and Technology Laboratory, UK (Dstl) titled “‘Efficacy of Finafloxacin against Biological Threat Agents” has been awarded a grant from the United States’ Defense Threat Reduction Agency (DTRA) Chemical and Biological Defense Program.

Singapore-headquartered health technology startup CXA Group (http://www.cxagroup.com/) has partnered with Philips and a select group of Fortune 500 companies to pilot an integrated workplace health solution, with the support of Singapore-based EDBI.

– With the Stanford Cancer Institute joining as a clinical trial partner, Tessa’s Phase III trial for nose cancer (nasopharyngeal cancer) is now widely accessible across multiple locations in the U.S.

Mountain View, CA: March 16, 2017 — Livongo Health, the leading consumer digital health company focused on chronic conditions, announced a $52.5 million growth round. The new funding round is co-led by existing investor General Catalyst and international investment company Kinnevik and joined by Singapore-based EDBI, American Investment Holdings LLC, and Microsoft Ventures. All previous investors participated in the current round as well.

Mountain View, CA: March 16, 2017 — Livongo Health, the leading consumer digital health company focused on chronic conditions, announced a $52.5 million growth round. The new funding round is co-led by existing investor General Catalyst and international investment company Kinnevik and joined by Singapore-based EDBI, American Investment Holdings LLC, and Microsoft Ventures.